923288-95-3

Basic information

• Product Name: Nilotinib hydrochloride anhydrous
• Synonyms: Nilotinib hydrochloride anhydrous;Nilotinib hydrochloride;4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(3-pyridinyl)-2-pyrimidinyl]amino}benzamide hydrochloride (1:1)
• CAS NO: 923288-95-3
• Molecular Formula: C28H23ClF3N7O
• Molecular Weight: 565.99
• Mol File: 923288-95-3.mol
• Article Data: 18

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Nilotinib hydrochloride anhydrous(CAS DataBase Reference)
• NIST Chemistry Reference: Nilotinib hydrochloride anhydrous(923288-95-3)
• EPA Substance Registry System: Nilotinib hydrochloride anhydrous(923288-95-3)

Safety Data

• Hazardous Substances Data: 923288-95-3(Hazardous Substances Data)

Usage

Uses

Nilotinib Hydrochloride might be useful in treatment of chronic myelogenous leukemia. It is a COVID19-related research product.

Upstream product

• 641571-10-0 nilotinib 
• 641571-11-1 3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)aniline 
• 915711-42-1 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-aminobenzamide 
• 1449570-25-5 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-nitrobenzamide hydrochloride 
• 1345336-53-9 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-guanidinobenzamide 

Relevant articles and documents

Method for preparing nilotinib monohydrochloride dihydrate crystal form A

The invention provides a method for preparing nilotinib monohydrochloride dihydrate crystal form A. Specifically, the method provided by the invention comprises the following steps: (1) mixing nilotinib a free alkali as shown in a formula I, hydrochloric

KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF

The present invention relates to kinase inhibitor C8-C16 aliphatic sulfate salts and compositions thereof.

PROCESS FOR THE PREPARATION OF PURE NILOTINIB AND ITS SALT

Object of the present invention is a process for the preparation of the pharmaceutical active ingredient Nilotinib free base or Nilotinib dihydrochloride dihydrate by means of an improved crystallization procedure.